Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986406 |
Synonyms | |
Therapy Description |
BMS-986406 is a monoclonal antibody that targets LILRB2 (ILT4), resulting in decreased downstream signaling and potentially leading to reduced immunosuppressive effects in the tumor microenvironment, and enhanced antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986406 | BMS986406|BMS 986406 | LILRB2 Antibody 11 | BMS-986406 is a monoclonal antibody that targets LILRB2 (ILT4), resulting in decreased downstream signaling and potentially leading to reduced immunosuppressive effects in the tumor microenvironment, and enhanced antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |